For Clinicians

MVI is developing safe immunotherapies for patients in all stages of prostate cancer.

MVI is committed to providing safe immunotherapy for all stages of prostate cancer, helping men live longer and with a higher quality of life.

What makes MVI therapies different

  • Enable checkpoint inhibitors to work in prostate cancer
  • Enable AR antagonists to work longer before resistance emerges
  • Safe and well-tolerated in metastatic and non-metastatic settings
  • No overlapping toxicities with checkpoint inhibitors or standard-of-care androgen receptor blocking agents
  • Ease of dosing
  • Affordable for combinations
  • Experience with multiple types of biomarkers, including Quantitative Total Bone Imaging (QTBI) to monitor impact of therapy on bone metastases

How do our therapies work?

The MVI immunotherapy solution involves two components:

  • MVI plasmid DNAs that activate immune cells to kill the tumors
  • Checkpoint inhibitors to block immunosuppressive mechanisms

We are working to delay time to metastases, and thus time to initiation of castration therapies, to preserve each patient's quality of life.

Clinical trials across all stages

We have clinical trials in progress that are targeting:

  • Non-metastatic, biochemically-recurrent prostate cancer
  • Metastatic, hormone-sensitive prostate cancer
  • Metastatic, castration-resistant prostate cancer

Stay in touch with MVI

We are always looking to speak and partner with clinicians working to offer their patients treatment regimens that will help maintain quality of life. We welcome you to get in touch.

Female pharma rep shaking hands with female doctor